Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects

Masayuki Kohno, Mari Haramoto, Oumi Nakajima, Liying Yang, Shiro Hinotsu, Masanao Yokohira, Katsumi Imaida, Koji Kawakami

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Corticosteroids are routinely used in patients with pulmonary fibrosis, yet they have several adverse effects. To improve this situation, we used an animal model of pulmonary injury and early fibrosis and investigated whether the combination of an intrapulmonary inhalation device with antedrug budesonide (BUD) administered to the lung had greater efficacy and fewer systemic adverse effects compared to long-acting dexamethasone (DEX). BUD or DEX was administrated either intrapulmonary or intravenously to bleomycin-treated rats. Antiinflammatory and antifibrotic effects were evaluated according to inflammatory cell count, total protein concentration and soluble collagen concentration in bronchoalveolar lavage fluid. The systemic immunosuppressive effects were also assessed by measuring body, spleen and thymus weight. BUD and DEX were compared with respect to their pharmacokinetic profiles in plasma and lung. Intrapulmonary treatment of BUD attenuates various inflammatory and early fibrotic indices with minimal systemic adverse effects compared with DEX. The area under the curve (AUC) of BUD by intrapulmonary spray was 6.6-fold higher than the AUC of DEX in the lung. This study suggests that antedrug BUD by intrapulmonary treatment has local anti-inflammatory and antifibrotic effects with minimal systemic adverse effects.

Original languageEnglish
Pages (from-to)1206-1211
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume33
Issue number7
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Budesonide
Bleomycin
Lung Injury
Dexamethasone
Lung
Area Under Curve
Anti-Inflammatory Agents
Therapeutics
Pulmonary Fibrosis
Nebulizers and Vaporizers
Bronchoalveolar Lavage Fluid
Immunosuppressive Agents
Thymus Gland
Adrenal Cortex Hormones
Fibrosis
Collagen
Spleen
Animal Models
Pharmacokinetics
Cell Count

Keywords

  • Antedrug
  • Corticosteroid
  • Drug delivery
  • Intrapulmonary treatment

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects. / Kohno, Masayuki; Haramoto, Mari; Nakajima, Oumi; Yang, Liying; Hinotsu, Shiro; Yokohira, Masanao; Imaida, Katsumi; Kawakami, Koji.

In: Biological and Pharmaceutical Bulletin, Vol. 33, No. 7, 2010, p. 1206-1211.

Research output: Contribution to journalArticle

Kohno, Masayuki ; Haramoto, Mari ; Nakajima, Oumi ; Yang, Liying ; Hinotsu, Shiro ; Yokohira, Masanao ; Imaida, Katsumi ; Kawakami, Koji. / Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects. In: Biological and Pharmaceutical Bulletin. 2010 ; Vol. 33, No. 7. pp. 1206-1211.
@article{70f2aa179eca4a18a44516206467337a,
title = "Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects",
abstract = "Corticosteroids are routinely used in patients with pulmonary fibrosis, yet they have several adverse effects. To improve this situation, we used an animal model of pulmonary injury and early fibrosis and investigated whether the combination of an intrapulmonary inhalation device with antedrug budesonide (BUD) administered to the lung had greater efficacy and fewer systemic adverse effects compared to long-acting dexamethasone (DEX). BUD or DEX was administrated either intrapulmonary or intravenously to bleomycin-treated rats. Antiinflammatory and antifibrotic effects were evaluated according to inflammatory cell count, total protein concentration and soluble collagen concentration in bronchoalveolar lavage fluid. The systemic immunosuppressive effects were also assessed by measuring body, spleen and thymus weight. BUD and DEX were compared with respect to their pharmacokinetic profiles in plasma and lung. Intrapulmonary treatment of BUD attenuates various inflammatory and early fibrotic indices with minimal systemic adverse effects compared with DEX. The area under the curve (AUC) of BUD by intrapulmonary spray was 6.6-fold higher than the AUC of DEX in the lung. This study suggests that antedrug BUD by intrapulmonary treatment has local anti-inflammatory and antifibrotic effects with minimal systemic adverse effects.",
keywords = "Antedrug, Corticosteroid, Drug delivery, Intrapulmonary treatment",
author = "Masayuki Kohno and Mari Haramoto and Oumi Nakajima and Liying Yang and Shiro Hinotsu and Masanao Yokohira and Katsumi Imaida and Koji Kawakami",
year = "2010",
doi = "10.1248/bpb.33.1206",
language = "English",
volume = "33",
pages = "1206--1211",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "7",

}

TY - JOUR

T1 - Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects

AU - Kohno, Masayuki

AU - Haramoto, Mari

AU - Nakajima, Oumi

AU - Yang, Liying

AU - Hinotsu, Shiro

AU - Yokohira, Masanao

AU - Imaida, Katsumi

AU - Kawakami, Koji

PY - 2010

Y1 - 2010

N2 - Corticosteroids are routinely used in patients with pulmonary fibrosis, yet they have several adverse effects. To improve this situation, we used an animal model of pulmonary injury and early fibrosis and investigated whether the combination of an intrapulmonary inhalation device with antedrug budesonide (BUD) administered to the lung had greater efficacy and fewer systemic adverse effects compared to long-acting dexamethasone (DEX). BUD or DEX was administrated either intrapulmonary or intravenously to bleomycin-treated rats. Antiinflammatory and antifibrotic effects were evaluated according to inflammatory cell count, total protein concentration and soluble collagen concentration in bronchoalveolar lavage fluid. The systemic immunosuppressive effects were also assessed by measuring body, spleen and thymus weight. BUD and DEX were compared with respect to their pharmacokinetic profiles in plasma and lung. Intrapulmonary treatment of BUD attenuates various inflammatory and early fibrotic indices with minimal systemic adverse effects compared with DEX. The area under the curve (AUC) of BUD by intrapulmonary spray was 6.6-fold higher than the AUC of DEX in the lung. This study suggests that antedrug BUD by intrapulmonary treatment has local anti-inflammatory and antifibrotic effects with minimal systemic adverse effects.

AB - Corticosteroids are routinely used in patients with pulmonary fibrosis, yet they have several adverse effects. To improve this situation, we used an animal model of pulmonary injury and early fibrosis and investigated whether the combination of an intrapulmonary inhalation device with antedrug budesonide (BUD) administered to the lung had greater efficacy and fewer systemic adverse effects compared to long-acting dexamethasone (DEX). BUD or DEX was administrated either intrapulmonary or intravenously to bleomycin-treated rats. Antiinflammatory and antifibrotic effects were evaluated according to inflammatory cell count, total protein concentration and soluble collagen concentration in bronchoalveolar lavage fluid. The systemic immunosuppressive effects were also assessed by measuring body, spleen and thymus weight. BUD and DEX were compared with respect to their pharmacokinetic profiles in plasma and lung. Intrapulmonary treatment of BUD attenuates various inflammatory and early fibrotic indices with minimal systemic adverse effects compared with DEX. The area under the curve (AUC) of BUD by intrapulmonary spray was 6.6-fold higher than the AUC of DEX in the lung. This study suggests that antedrug BUD by intrapulmonary treatment has local anti-inflammatory and antifibrotic effects with minimal systemic adverse effects.

KW - Antedrug

KW - Corticosteroid

KW - Drug delivery

KW - Intrapulmonary treatment

UR - http://www.scopus.com/inward/record.url?scp=77954511345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954511345&partnerID=8YFLogxK

U2 - 10.1248/bpb.33.1206

DO - 10.1248/bpb.33.1206

M3 - Article

VL - 33

SP - 1206

EP - 1211

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 7

ER -